Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 8277831
Drug-enhanced adhesion prevention
granted -
US 8277797
Interferon-Ξ² production modulating Listeria strains and methods for using same
granted -
US 8278293
Diazo bicyclic Smac mimetics and the uses thereof
granted -
US 8273867
Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS
granted -
US 8273729
Treatment of irritable bowel syndrome and related bowel disease
granted -
US 8273746
Methods involving aldose reductase inhibitors
granted -
US 8275594
Engineered scaffolds for intervertebral disc repair and regeneration and for articulating joint repair and regeneration
granted -
US 8274643
Porous nanostructures and methods involving the same
granted -
US 8268849
Multifunctional Antioxidants and methods of use thereof
granted -
US 8268344
Particle-containing complex porous materials
granted -
US 8268825
Method for the treatment of anthrax infections
granted -
US 8263095
Methods of use for peptides having activities of insulin like growth factor-1
granted -
US 8263133
Multivalent clustering targeting strategy for drug carriers
granted -
US 8263747
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
granted -
US 8263662
Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine products
granted -
US 8263651
Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors
granted -
US 8263661
Development of new selective estrogen receptor modulators
granted -
US 8263085
Gammaretrovirus associated with cancer
granted -
US 8258163
Small-molecule agonists for type-2 orexin receptor
granted -
US 8258257
Claudin-4 binding peptides, compositions and methods of use
granted -
US 8257918
Intelligent nanomedicine integrating diagnosis and therapy
granted -
US 8258263
Interferon-antibody fusion proteins demonstrating potent apoptotic and anti-tumor activities
granted -
US 8258274
Vaccines containing canine parvovirus genetic variants
granted -
US 8257932
Interfacing nanostructures to biological cells
granted -
US 8252836
Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
granted -
US 8252338
Synthetic LDL as targeted drug delivery vehicle
granted -
US 8252737
Antimicrobial peptides and methods of use
granted -
US 8252280
MAPC generation of muscle
granted -
US 8252841
Methods of inhibiting bacterial virulence and compounds relating thereto
granted -
US 8252807
Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
granted -
US 8252764
Compositions and methods of use of targeting peptides against placenta and adipose tissues
granted -
US 8252574
Pseudoinfectious flavivirus and uses thereof
granted -
US 8251941
Selective cytopheresis devices and related methods thereof
granted -
US 8246952
Method of increasing radiation sensitivity by inhibition of beta one integrin
granted -
US 8247399
Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
granted -
US 8247181
Borrelia diagnostics and screening methods
granted -
US 8247174
Methods of diagnosing endometriosis
granted -
US 8241863
Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors
granted -
US 8242142
Cyclohexylamines, phenylamines and uses thereof
granted -
US 8242109
Compositions and methods relating to novel compounds and targets thereof
granted -
US 8241651
Multiphasic biofunctional nano-components and methods for use thereof
granted -
US 8242170
Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
granted -
US 8242093
Rescue of photoreceptors by intravitreal administration of an expression vector encoding a therapeutic protein
granted -
US 8242080
Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface
granted -
US 8236983
Composition and method for the treatment of diseases affected by apoptosis
granted -
US 8236335
Antimicrobial nanoemulsion compositions and methods
granted -
US 8236279
Bisaminoethanethiol-targeting ligand conjugates and compositions
granted -
US 8236754
Methods for improving the structure and function of arterioles
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory